NCT05516407View on ClinicalTrials.gov

Safety and Efficacy of Oral Full-Spectrum Medicinal Cannabis Plant Extract in Children With Autism Spectrum Disorder.

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

September 1, 2022

Study Completion Date

September 2, 2022

Conditions
Autism Spectrum Disorder
Interventions
DRUG

FEN164

Oil based. Full-spectrum medicinal cannabis plant extract with less than 0.08% THC.

Trial Locations (1)

3168

Monash Children's Hospital, Clayton

Sponsors
All Listed Sponsors
collaborator

Neurotech International Limited

INDUSTRY

collaborator

Monash Health

OTHER

lead

Fenix Innovation Group

INDUSTRY